Last reviewed · How we verify

CSII followed by Lina

Sun Yat-sen University · FDA-approved active Small molecule

CSII (continuous subcutaneous insulin infusion) followed by liraglutide (Lina) provides basal-bolus insulin delivery combined with GLP-1 receptor agonism to improve glycemic control in diabetes.

CSII (continuous subcutaneous insulin infusion) followed by liraglutide (Lina) provides basal-bolus insulin delivery combined with GLP-1 receptor agonism to improve glycemic control in diabetes. Used for Type 2 diabetes mellitus requiring intensive glycemic control.

At a glance

Generic nameCSII followed by Lina
Also known asCSII+Lina
SponsorSun Yat-sen University
Drug classCombination therapy: insulin (basal-bolus) + GLP-1 receptor agonist
TargetInsulin receptor (CSII component); GLP-1 receptor (liraglutide component)
ModalitySmall molecule
Therapeutic areaEndocrinology / Diabetes
PhaseFDA-approved

Mechanism of action

This combination therapy uses an insulin pump (CSII) to deliver continuous background insulin with meal-time boluses, while liraglutide enhances insulin secretion, slows gastric emptying, and promotes satiety through GLP-1 receptor activation. The sequential or concurrent use aims to optimize blood glucose management while potentially reducing insulin requirements and supporting weight loss.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: